» Articles » PMID: 33100921

Laboratory Optimization Tweaks for Sanger Sequencing in a Resource-Limited Setting

Overview
Journal J Biomol Tech
Date 2020 Oct 26
PMID 33100921
Authors
Affiliations
Soon will be listed here.
Abstract

Despite various challenges that hinder the implementation of high-tech molecular methods in resource-limited settings, we have been able to implement and achieve International Organization for Standardization 15189:2012 accreditation for genotypic HIV drug resistance testing in our facility. At the Center for Human Virology and Genomics, Nigerian Institute of Medical Research, Nigeria has recorded a high sequencing success rate and good quality sequence data. This was achieved by optimizing laboratory processes from 2008 to the current date. We have optimized sample preparation, RT-PCR, several post-PCR processes, and the cycle sequencing to improve the sensitivity of amplification even with limited plasma samples and low viral copy numbers. The optimized workflow maximizes output, minimizes reagent wastage, and achieves substantial cost savings without compromising the quality of the sequence data. Our performance at our last external quality assurance program is a testimonial to the efficiency of the workflow. For the 5-sample panel, each with 67-68 mutation points evaluated, we scored 100% for all 5 specimens. Our optimized laboratory workflow is thus documented to support laboratories and to help researchers achieve excellent results the first time and eliminate contamination while minimizing the wastage of costly sequencing reagents.

References
1.
Lapointe H, Dong W, Lee G, Bangsberg D, Martin J, Mocello A . HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument. Antimicrob Agents Chemother. 2015; 59(11):6824-33. PMC: 4604392. DOI: 10.1128/AAC.01490-15. View

2.
Rhee S, Jordan M, Raizes E, Chua A, Parkin N, Kantor R . HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS One. 2015; 10(12):e0145772. PMC: 4696791. DOI: 10.1371/journal.pone.0145772. View

3.
Inzaule S, Ondoa P, Peter T, Mugyenyi P, Stevens W, Wit T . Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infect Dis. 2016; 16(11):e267-e275. DOI: 10.1016/S1473-3099(16)30118-9. View

4.
Pattery T, Verlinden Y, De Wolf H, Nauwelaers D, Van Baelen K, Van Houtte M . Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance. Intervirology. 2012; 55(2):138-46. DOI: 10.1159/000332013. View

5.
Zhou Z, Wagar N, DeVos J, Rottinghaus E, Diallo K, Nguyen D . Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One. 2011; 6(11):e28184. PMC: 3223235. DOI: 10.1371/journal.pone.0028184. View